|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,010 JPY | +5.12% |
|
+8.07% | +29.39% |
| Apr. 25 | Scholz pledges further support for the pharmaceutical industry | DP |
| Apr. 25 | Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024 | MT |
March 11 (Reuters) - Daiichi Sankyo Co Ltd:
* ON MARCH 8, QUIZARTINIB APPROVED TO TREAT ADULT PATIENTS WITH ACUTE MYELOID LEUKAEMIA Source text for Eikon: Further company coverage:
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 5,010 JPY | +5.12% | +8.07% | 61.03B | ||
| 2,686 PTS | +0.86% | +0.34% | - | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +29.39% | 61.03B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
DAIICHI SANKYO CO., LTD. 
